Noxopharm Ltd (NOX) - Net Assets

Latest as of June 2025: AU$689.96K AUD ≈ $488.19K USD

Based on the latest financial reports, Noxopharm Ltd (NOX) has net assets worth AU$689.96K AUD (≈ $488.19K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$4.58 Million ≈ $3.24 Million USD) and total liabilities (AU$3.89 Million ≈ $2.75 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Noxopharm Ltd (NOX) asset resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	AU$689.96K
% of Total Assets	15.06%
Annual Growth Rate	-21.28%
5-Year Change	-98.31%
10-Year Change	N/A
Growth Volatility	147.12

Noxopharm Ltd - Net Assets Trend (2016–2025)

This chart illustrates how Noxopharm Ltd's net assets have evolved over time, based on quarterly financial data. Also explore NOX asset base for the complete picture of this company's asset base.

Annual Net Assets for Noxopharm Ltd (2016–2025)

The table below shows the annual net assets of Noxopharm Ltd from 2016 to 2025. For live valuation and market cap data, see NOX stock market capitalisation.

Year	Net Assets	Change
2025-06-30	AU$689.96K ≈ $488.19K	-87.44%
2024-06-30	AU$5.50 Million ≈ $3.89 Million	-39.44%
2023-06-30	AU$9.07 Million ≈ $6.42 Million	-62.38%
2022-06-30	AU$24.12 Million ≈ $17.06 Million	-40.85%
2021-06-30	AU$40.78 Million ≈ $28.85 Million	+216.76%
2020-06-30	AU$12.87 Million ≈ $9.11 Million	+987.49%
2019-06-30	AU$-1.45 Million ≈ $-1.03 Million	-114.29%
2018-06-30	AU$10.15 Million ≈ $7.18 Million	+311.26%
2017-06-30	AU$2.47 Million ≈ $1.75 Million	-58.50%
2016-06-30	AU$5.95 Million ≈ $4.21 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Noxopharm Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 7404567300.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component	Amount	Percentage
Common Stock	AU$74.64 Million	10817.35%
Other Comprehensive Income	AU$700.06K	101.46%
Other Components	AU$1.00	0.00%
Total Equity	AU$689.96K	100.00%

Noxopharm Ltd Competitors by Market Cap

The table below lists competitors of Noxopharm Ltd ranked by their market capitalization.

Company	Market Cap
Khind Holdings Bhd KLSE:7062	$15.52 Million
Betonjaya Manunggal Tbk JK:BTON	$15.53 Million
Akdeniz Yatirim Holding AS IS:AKYHO	$15.53 Million
Nuchev Ltd AU:NUC	$15.53 Million
Megapolitan Developments Tbk JK:EMDE	$15.51 Million
Electro-Sensors Inc NASDAQ:ELSE	$15.51 Million
Macompta Fr Sa PA:MLMCA	$15.50 Million
Asuransi Jasa Tania Tbk JK:ASJT	$15.50 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Noxopharm Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 5,495,144 to 689,963, a change of -4,805,181 (-87.4%).
Net loss of 4,884,170 reduced equity.
Other comprehensive income decreased equity by 229,703.
Other factors increased equity by 308,692.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	AU$-4.88 Million	-707.89%
Other Comprehensive Income	AU$-229.70K	-33.29%
Other Changes	AU$308.69K	+44.74%
Total Change	AU$-	-87.44%

Book Value vs Market Value Analysis

This analysis compares Noxopharm Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 31.79x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 0.42x to 31.79x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-06-30	AU$0.18	AU$0.08	x
2017-06-30	AU$0.03	AU$0.08	x
2018-06-30	AU$0.10	AU$0.08	x
2019-06-30	AU$0.00	AU$0.08	x
2020-06-30	AU$0.09	AU$0.08	x
2021-06-30	AU$0.15	AU$0.08	x
2022-06-30	AU$0.08	AU$0.08	x
2023-06-30	AU$0.03	AU$0.08	x
2024-06-30	AU$0.02	AU$0.08	x
2025-06-30	AU$0.00	AU$0.08	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Noxopharm Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -707.89%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -173.15%
• Asset Turnover: 0.62x
• Equity Multiplier: 6.64x
Recent ROE (-707.89%) is below the historical average (-135.68%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	-11.85%	-195756.94%	0.00x	1.04x	AU$-1.30 Million
2017	-123.44%	-2411.66%	0.04x	1.15x	AU$-3.29 Million
2018	-180.17%	-1994.85%	0.06x	1.43x	AU$-19.30 Million
2019	0.00%	-299.22%	0.87x	0.00x	AU$-11.21 Million
2020	-2.11%	-3.29%	0.41x	1.56x	AU$-1.56 Million
2021	-22.92%	-166.66%	0.12x	1.17x	AU$-13.42 Million
2022	-77.40%	-343.86%	0.20x	1.10x	AU$-21.08 Million
2023	-165.94%	-250.52%	0.59x	1.12x	AU$-15.96 Million
2024	-65.11%	-149.07%	0.35x	1.23x	AU$-4.13 Million
2025	-707.89%	-173.15%	0.62x	6.64x	AU$-4.95 Million

Industry Comparison

This section compares Noxopharm Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $13,951,937
Average return on equity (ROE) among peers: -63.22%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Noxopharm Ltd (NOX)	AU$689.96K	-11.85%	5.64x	$15.51 Million
Adalta Ltd (1AD)	$5.38 Million	-112.69%	0.98x	$8.12 Million
Algorae Pharmaceuticals Ltd (1AI)	$5.53 Million	-110.79%	0.18x	$20.04 Million
ACRUX Ltd (ACR)	$43.92 Million	-0.55%	0.08x	$3.49 Million
Actinogen Medical Ltd (ACW)	$15.66 Million	-63.12%	0.04x	$103.45 Million
Argenica Therapeutics Ltd (AGN)	$13.95 Million	-39.28%	0.17x	$15.45 Million
Arovella Therapeutics Ltd (ALA)	$8.35 Million	-58.19%	0.43x	$66.62 Million
Anatara Lifesciences Ltd (ANR)	$3.83 Million	-52.11%	0.13x	$1.57 Million
Alterity Therapeutics Ltd (ATH)	$30.47 Million	-50.24%	0.10x	$80.80 Million
Amplia Therapeutics Ltd (ATX)	$9.77 Million	-46.00%	0.04x	$54.45 Million
Avecho Biotechnology Ltd (AVE)	$2.65 Million	-99.27%	0.26x	$31.19 Million

About Noxopharm Ltd

AU:NOX Australia Biotechnology

Market Cap

$15.51 Million

AU$21.92 Million AUD

Market Cap Rank

#25755 Global

#1186 in Australia

Share Price

AU$0.08

Change (1 day)

+7.14%

52-Week Range

AU$0.04 - AU$0.13

All Time High

AU$1.58